NCT00544791

The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment

The Effect of Melatonin on Memory and Other Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment (MCI): A Placebo- Controlled Study.

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Assaf-Harofeh Medical Center · Other Government
• Sex: All
• Age: 55 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Recent studies have described the role of melatonin as a sleep regulator and as an anti- oxidative neuroprotective agent in improving sleep quality and delaying cognitive decline in Alzheimer's disease (AD). In accordance with this data, our hypothesis is that melatonin will delay the cognitive decline in Mild Cognitive Impairment (MCI) patients and reduce the conversion rate from MCI to AD.

Conditions

• Mild Cognitive Impairment (MCI)

Interventions

Type	Name	Description
DRUG	melatonin	5 mg, oral, daily dose for 6 months
DRUG	placebo like melatonin tablets

Timeline

• Start date: 2007-10-01
• Completion: 2010-10-01
• First posted: 2007-10-16
• Last updated: 2007-10-16

Locations

1 site across 1 country: Israel